BIO Bio-Rad Laboratories Inc
Price (delayed)
$238.18
Market cap
$6.67B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$65.36
Enterprise value
$7.56B
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley,
Highlights
The company's quick ratio rose by 13% YoY and by 8% QoQ
The debt has declined by 2.2% year-on-year
The EPS has plunged by 200% YoY and by 137% from the previous quarter
The net income has shrunk by 189% YoY and by 137% QoQ
Key stats
What are the main financial stats of BIO
Market
Valuations
Earnings
Shares outstanding
28.01M
Market cap
$6.67B
Enterprise value
$7.56B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.02
Price to sales (P/S)
2.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.94
Revenue
$2.57B
Gross profit
$1.38B
Operating income
$269M
Net income
-$1.84B
EBIT
-$2.29B
EBITDA
-$2.29B
Free cash flow
$289.7M
Per share
Balance sheet
Liquidity
EPS
-$65.36
EPS diluted
-$65.36
Free cash flow per share
$10.27
Book value per share
$234.64
Revenue per share
$90.97
TBVPS
$306.94
Total assets
$9.36B
Total liabilities
$2.79B
Debt
$1.37B
Equity
$6.57B
Working capital
$2.56B
Debt to equity
0.21
Current ratio
6.48
Quick ratio
4.53
Net debt/EBITDA
-0.39
Margins
Efficiency
Dividend
EBITDA margin
-89.4%
Gross margin
53.7%
Net margin
-71.9%
Operating margin
10.5%
Return on assets
-17.5%
Return on equity
-24.7%
Return on invested capital
-22.2%
Return on capital employed
-25.8%
Return on sales
-89.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BIO stock price
How has the Bio-Rad Laboratories stock price performed over time
Intraday
-2.87%
1 week
2.54%
1 month
-7.32%
1 year
-18.11%
YTD
-27.5%
QTD
-2.21%
Financial performance
How have Bio-Rad Laboratories's revenue and profit performed over time
Revenue
$2.57B
Gross profit
$1.38B
Operating income
$269M
Net income
-$1.84B
Gross margin
53.7%
Net margin
-71.9%
The net income has shrunk by 189% YoY and by 137% QoQ
The net margin has dropped by 138% since the previous quarter
BIO's operating income is down by 20% year-on-year and by 12% since the previous quarter
BIO's operating margin is down by 17% year-on-year and by 12% since the previous quarter
Growth
What is Bio-Rad Laboratories's growth rate over time
Valuation
What is Bio-Rad Laboratories stock price valuation
P/E
N/A
P/B
1.02
P/S
2.62
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.94
The EPS has plunged by 200% YoY and by 137% from the previous quarter
BIO's P/B is 32% below its 5-year quarterly average of 1.5 and 15% below its last 4 quarters average of 1.2
The equity has contracted by 25% YoY and by 12% from the previous quarter
The stock's price to sales (P/S) is 49% less than its 5-year quarterly average of 5.1 and 25% less than its last 4 quarters average of 3.5
The revenue has contracted by 3.9% YoY
Efficiency
How efficient is Bio-Rad Laboratories business performance
The ROS has plunged by 198% YoY and by 141% from the previous quarter
The company's return on invested capital has shrunk by 158% QoQ
The ROE has dropped by 155% since the previous quarter
Bio-Rad Laboratories's ROA has plunged by 154% from the previous quarter
Dividends
What is BIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BIO.
Financial health
How did Bio-Rad Laboratories financials performed over time
The total assets has declined by 24% year-on-year and by 12% since the previous quarter
BIO's total liabilities is down by 21% year-on-year and by 10% since the previous quarter
The debt is 79% smaller than the equity
Bio-Rad Laboratories's debt to equity has increased by 31% YoY and by 11% from the previous quarter
The equity has contracted by 25% YoY and by 12% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.